CSPC Pharmaceutical Group Limited Share Price
Stocks
1093
HK1093012172
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Hong Kong S.E.
08:08:17 13/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 8.030 HKD | -4.35% |
|
-4.97% | -4.74% |
| 11-06 | CSPC Pharma Begins Trial of Pulmonary Fibrosis Drug in China | MT |
| 11-06 | CSPC Pharma Begins Trial of B-cell non-Hodgkin Lymphoma Drug in China | MT |
| Market Cap | 91.67B 11.68B 10.59B 9.79B 8.84B 16.65B 1,102B 17.24B 118B 46.65B 589B 43.85B 42.92B 1,868B | P/E 2026 * |
9.03x | P/E 2027 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise Value | 80.44B 10.25B 9.29B 8.59B 7.75B 14.61B 967B 15.13B 103B 40.93B 516B 38.48B 37.66B 1,639B | EV / Sales 2026 * |
2.09x | EV / Sales 2027 * | 2.16x |
| Free-Float |
67.42% | Yield 2026 * |
5.73% | Yield 2027 * | 4.59% |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 1093 | Delayed | |
Tradegate
| CVG | Real-time | |
|
OTC Markets
| CHJTF | Delayed | |
|
Boerse Muenchen
| CVG | Real-time | |
|
Deutsche Boerse AG
| CVG | Delayed | |
|
Börse Stuttgart
| CVG | Delayed |
| 1 day | -4.35% | ||
| 1 week | -4.97% | ||
| Current month | +2.10% | ||
| 1 month | -8.85% | ||
| 3 months | -7.59% | ||
| 6 months | +0.88% | ||
| Current year | -4.74% |
| 1 week | 8 |  | 8.68 |
| 1 month | 7.6 | | 9.19 |
| Current year | 6.53 | | 10.96 |
| 1 year | 6.53 | | 10.96 |
| 3 years | 4.27 | | 11.63 |
| 5 years | 4.27 | | 11.63 |
| 10 years | 3.87 | | 13.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
George Cai
CEO | Chief Executive Officer | 46 | 18/12/2025 |
Qing Jie Wei
COO | Chief Operating Officer | 56 | 18/12/2025 |
Zhi Yong Qu
PRN | Corporate Officer/Principal | 44 | 30/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 72 | 25/08/2011 |
Zhen Guo Wang
BRD | Director/Board Member | 56 | 19/01/2012 |
Bo Wang
BRD | Director/Board Member | 66 | 20/12/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 23/06/26 | Other | Director | -700,000 | 0.0061% | ||
| 29/05/26 | Other | Chairman | 9,402,000 | 0.0816% | ||
| 28/05/26 | Other | Chairman | 40,000,000 | 0.3471% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.35% | -4.97% | +1.13% | +17.57% | 11.68B | |
| +1.26% | +6.61% | +40.79% | +136.32% | 1,286B | |
| +0.79% | +3.45% | +45.84% | +93.52% | 688B | |
| +0.20% | +1.28% | +26.97% | +113.70% | 521B | |
| -0.44% | +3.69% | +41.45% | +68.91% | 386B | |
| +0.55% | +0.70% | +59.02% | +44.62% | 364B | |
| -0.12% | +0.74% | +28.39% | +58.54% | 302B | |
| +0.37% | +0.37% | +3.33% | +37.27% | 287B | |
| -0.30% | +1.14% | +38.29% | +72.46% | 252B | |
| +0.08% | +0.71% | +34.44% | +124.95% | 208B | |
| Average | -0.20% | +1.37% | +31.97% | +76.78% | 431B | |
| Weighted average by Cap. | +0.52% | +3.23% | +37.60% | +96.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.51B 4.91B 4.45B 4.11B 3.71B 6.99B 463B 7.24B 49.42B 19.6B 247B 18.42B 18.03B 785B | 35.84B 4.57B 4.14B 3.83B 3.45B 6.51B 431B 6.74B 45.99B 18.24B 230B 17.14B 16.78B 730B |
| Net income | 10.15B 1.29B 1.17B 1.08B 978M 1.84B 122B 1.91B 13.03B 5.17B 65.16B 4.85B 4.75B 207B | 6.99B 891M 807M 746M 673M 1.27B 83.97B 1.31B 8.97B 3.56B 44.85B 3.34B 3.27B 142B |
| Net Debt | -11.23B -1.43B -1.3B -1.2B -1.08B -2.04B -135B -2.11B -14.42B -5.72B -72.12B -5.37B -5.26B -229B | -14.31B -1.82B -1.65B -1.53B -1.38B -2.6B -172B -2.69B -18.36B -7.28B -91.85B -6.84B -6.7B -292B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/11/26 | HK$8.030 | -4.35% | 64,343,476 |
| 12/11/26 | HK$8.395 | -1.58% | 48,572,322 |
| 11/11/26 | HK$8.530 | -1.10% | 64,814,116 |
| 10/11/26 | HK$8.625 | +2.31% | 70,948,823 |
| 09/11/26 | HK$8.430 | -0.24% | 46,023,127 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- 1093 Stock
Select your edition
All financial news and data tailored to specific country editions
